Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Stock Information for Apollomics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Apollomics Inc.

Apollomics Announces Settlement of Cayman Litigation
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Nasdaq Resumes Trading in Apollomics Inc.
Apollomics, Inc. Company Operational Continuity Update
Nasdaq Halts Apollomics Inc., Ltd.
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.